<- Go Home
Allakos Inc.
Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Market Cap
$29.7M
Volume
1.0M
Cash and Equivalents
$24.2M
EBITDA
-$88.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.55
52 Week Low
$0.22
Dividend
N/A
Price / Book Value
0.54
Price / Earnings
-0.41
Price / Tangible Book Value
0.54
Enterprise Value
-$25.5M
Enterprise Value / EBITDA
0.29
Operating Income
-$99.7M
Return on Equity
88.87%
Return on Assets
-52.64
Cash and Short Term Investments
$55.2M
Debt
N/A
Equity
$55.5M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium